Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
RBC Capital Maintains Outperform on Trade Desk, Raises Price Target to $80
RBC Capital analyst Matthew Hedberg maintains Trade Desk (NASDAQ:TTD) with a Outperform and raises the price target from $75 to $80.
